Zipeprol

Summary

Zipeprol (CHEMBL2105497) is an approved small molecule (ATC R05DB15); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R05DB15
• Indications: 1 condition
• Chemistry: 384.5 Da · C23H32N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105497
Name	Zipeprol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	36910
ATC	R05DB15
Molecular formula	C23H32N2O3
Molecular weight	384.5
InChIKey	VSTNNAYSCJQCQI-UHFFFAOYSA-N

SMILES: COC(CN1CCN(CC1)CC(C(C2=CC=CC=C2)OC)O)C3=CC=CC=C3

IUPAC name: 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol

Also known as: Dea no. 9873, Zipeprol, Zo-tab, ZIPEPROL

Patent coverage: 138 distinct patent families (506 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).